These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1180 related articles for article (PubMed ID: 3149043)

  • 1. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
    Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
    Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
    Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
    Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems.
    Gevers Leuven JA; Kluft C; Bertina RM; Hessel LW
    J Lab Clin Med; 1987 Jun; 109(6):631-6. PubMed ID: 3108429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease.
    Nikfardjam M; Graf S; Beckmann R; Hornykewycz S; Koller-Strametz J; Binder BR; Huber K
    Thromb Haemost; 1999 Sep; 82 Suppl 1():80-4. PubMed ID: 10695493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
    J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balance of coagulation activity with fibrinolysis during use of oral contraceptives in women with insulin-dependent diabetes mellitus.
    Petersen KR; Skouby SO; Jespersen J
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():105-11. PubMed ID: 8574252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
    Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
    Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
    Hamsten A; Wiman B; de Faire U; Blombäck M
    N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle.
    Jespersen J; Kluft C
    Thromb Haemost; 1986 Jun; 55(3):388-9. PubMed ID: 3092396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.